Navigation Links
Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech

Epinex Test Could Transform Diabetes Care

IRVINE, Calif., March 26 /PRNewswire/ -- On March 18th, Frost & Sullivan presented Epinex with its prestigious global diabetes research award. The award was given in recognition of Epinex's innovative G1A(TM) Rapid Diabetes Monitoring Index Test, which uses glycated albumin to measure the damage caused by excess sugar in the body.


Diabetes is one of the biggest contributors to our healthcare crisis. Preventive care programs could significantly reduce the human and financial costs of diabetes. The impending shift to preventive care has opened the door for a small company like Epinex to make a big difference in the healthcare system and in the lives of diabetics. The Epinex G1A(TM) test has the potential to transform diabetes care by introducing a more effective monthly diabetes management paradigm.

Preventive care will drive healthcare policy in the future. In his effort to revamp our crippled healthcare system, President Obama has called for investing unprecedented resources into preventive health care. President Obama once again targeted healthcare reform as the best way to "bend the curve on...deficit projections" at his news conference on Tuesday.

"The current economic crisis has leveled the playing field between Main Street and Wall Street," declared Epinex CEO Asad Zaidi during his acceptance speech. "As a Main Street biotech company, this award validates our work and will motivate us to...bring paradigm shifting disruptive technology into the marketplace. This award gives us the energy and momentum to break through the resistance of established medical practices."

The Obama Administration has called for "tough choices" in cutting medical costs. Healthcare companies are challenged to respond by investing in innovative products that will meet future healthcare needs. Epinex's award-winning research has been recognized as a step forward in meeting that challenge.

About Epinex Diagnostics, Inc.

Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests. Please find further information about the company and the G1A(TM) test at

    Jacqueline Morales
    Public Relations
    Epinex Diagnostics, Inc.
    Phone 949-660-7770, ext. 106

SOURCE Epinex Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
2. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
3. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
4. Frost & Sullivan: In Vitro Diagnostics Market
5. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
6. Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG
7. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
8. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
9. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
10. Frost & Sullivan to Present the 2009 Excellence in Medical Technologies & Life Sciences Awards
11. Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence
Post Your Comments:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):